Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2006 2
2007 2
2008 3
2009 9
2010 8
2011 2
2012 4
2013 5
2014 6
2015 2
2016 6
2017 3
2018 1
2019 6
2020 19
2021 28
2022 18
2023 20
2024 18
2025 12
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.
Shumaker AH, Bhimraj A, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Shafer RW, Tien PC, Baden LR, Cawcutt K, Chiotos K, Dzierba AL, Hardy EJ, Johnson S, Kim AY, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Oliveira CR, Pearson JC, Riley L, Shoham S, Tebas P, Willis Z, Wolf J, Loveless J, Morgan RL, Falck-Ytter Y, Gandhi RT. Shumaker AH, et al. Among authors: shoham s. Clin Infect Dis. 2026 Apr 1:ciaf680. doi: 10.1093/cid/ciaf680. Online ahead of print. Clin Infect Dis. 2026. PMID: 41920902 Free article.
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.
Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, MacBrayne C, Nakamura MM, Oliveira CR, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Willis Z, Wolf J, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT. Nadig N, et al. Among authors: shoham s. Clin Infect Dis. 2026 Apr 1:ciaf681. doi: 10.1093/cid/ciaf681. Online ahead of print. Clin Infect Dis. 2026. PMID: 41920901 Free article.
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study.
Maertens J, Chen SCA, Thompson GR 3rd, Donovan F, Dane A, Birch M, Pinder C, Bennett J, Ravenna V, Marin Fernandez O, Ross G, Zinzi D, Rex JH; Phase 2b Olorofim Salvage Therapy Study Group. Maertens J, et al. J Antimicrob Chemother. 2026 Mar 4;81(4):dkag118. doi: 10.1093/jac/dkag118. J Antimicrob Chemother. 2026. PMID: 41914555 Free PMC article. Clinical Trial.
Corticosteroid Therapy and Long-Term Outcomes of Post-Infectious Inflammatory Syndrome in Non-HIV Immunosuppressed Cryptococcal Meningitis: A Multicenter Case Series.
Ito Y, Hoeltermann TA, Anjum S, Robinson L, Little JS, Kiritsy M, Steinbrink JM, Finocchi A, Walker LW, Avery RK, Shoham S, Beaird OE, Ong SC, Van Dam CN, Stephens I, Haleem A, Williamson PR. Ito Y, et al. Among authors: shoham s. J Infect Dis. 2026 Feb 18;233(2):e553-e560. doi: 10.1093/infdis/jiaf620. J Infect Dis. 2026. PMID: 41486473 Free PMC article.
Clinical trial coordination of multifaceted ethical and regulatory oversight entities during the COVID-19 public health emergency.
Gawad A, Mendoza J, Singleton M, Majkowski R, Hopkins E, Carll J, MacInnis C, Amirault D, Jackson B, McBee N, Mould A, Eyzaguirre LM, Pessoa-Gingerich C, Shoham S, Sullivan D, Lane K. Gawad A, et al. Among authors: shoham s. Contemp Clin Trials. 2026 Feb;161:108207. doi: 10.1016/j.cct.2025.108207. Epub 2025 Dec 24. Contemp Clin Trials. 2026. PMID: 41453518 Free PMC article.
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.
Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT. Nadig N, et al. Among authors: shoham s. Clin Infect Dis. 2026 Jan 16;81(Suppl 3):i17-i21. doi: 10.1093/cid/ciaf354. Clin Infect Dis. 2026. PMID: 40923137 Free PMC article.
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.
Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT. Nadig N, et al. Among authors: shoham s. Clin Infect Dis. 2026 Jan 16;81(Suppl 3):i22-i26. doi: 10.1093/cid/ciaf355. Clin Infect Dis. 2026. PMID: 40831386 Free article.
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.
Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. Bhimraj A, et al. Among authors: shoham s. Clin Infect Dis. 2026 Jan 16;81(Suppl 3):i1-i5. doi: 10.1093/cid/ciaf424. Clin Infect Dis. 2026. PMID: 40757658 Free article.
171 results